Dynavax Technologies Corp. (NASDAQ:DVAX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “

Several other equities research analysts have also recently weighed in on the company. Cowen and Company reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Dynavax Technologies Corp. in a research note on Tuesday, September 6th. RBC Capital Markets set a $4.00 price target on Dynavax Technologies Corp. and gave the stock a “hold” rating in a research note on Monday. William Blair reaffirmed a “buy” rating and issued a $45.00 price target on shares of Dynavax Technologies Corp. in a research note on Tuesday, September 6th. Finally, S&P Equity Research upped their price target on Dynavax Technologies Corp. from $11.28 to $16.01 in a research note on Friday, September 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $24.14.

Analyst Recommendations for Dynavax Technologies Corp. (NASDAQ:DVAX)

Dynavax Technologies Corp. (NASDAQ:DVAX) traded down 3.16% during midday trading on Wednesday, hitting $4.60. The stock had a trading volume of 2,773,546 shares. The firm has a 50 day moving average of $10.15 and a 200 day moving average of $13.64. Dynavax Technologies Corp. has a 52 week low of $3.20 and a 52 week high of $29.86. The firm’s market cap is $177.22 million.

Dynavax Technologies Corp. (NASDAQ:DVAX) last issued its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by $0.15. The firm earned $0.20 million during the quarter, compared to analysts’ expectations of $2.44 million. Dynavax Technologies Corp. had a negative return on equity of 78.57% and a negative net margin of 2,650.25%. Dynavax Technologies Corp.’s revenue for the quarter was down 83.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.82) earnings per share. Equities research analysts predict that Dynavax Technologies Corp. will post ($3.21) EPS for the current year.

Several large investors have recently added to or reduced their stakes in the stock. Emerald Acquisition Ltd. acquired a new stake in Dynavax Technologies Corp. during the second quarter valued at approximately $472,000. California State Teachers Retirement System boosted its stake in Dynavax Technologies Corp. by 5.0% in the second quarter. California State Teachers Retirement System now owns 81,505 shares of the biopharmaceutical company’s stock valued at $1,188,000 after buying an additional 3,851 shares during the period. CAM Group Holding A S boosted its stake in Dynavax Technologies Corp. by 18.8% in the second quarter. CAM Group Holding A S now owns 189,962 shares of the biopharmaceutical company’s stock valued at $2,770,000 after buying an additional 30,000 shares during the period. Blair William & Co. IL boosted its stake in Dynavax Technologies Corp. by 17.9% in the second quarter. Blair William & Co. IL now owns 377,772 shares of the biopharmaceutical company’s stock valued at $4,607,000 after buying an additional 57,225 shares during the period. Finally, GW&K Investment Management LLC boosted its stake in Dynavax Technologies Corp. by 13.3% in the second quarter. GW&K Investment Management LLC now owns 160,213 shares of the biopharmaceutical company’s stock valued at $2,336,000 after buying an additional 18,794 shares during the period. 85.18% of the stock is currently owned by institutional investors.

About Dynavax Technologies Corp.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

5 Day Chart for NASDAQ:DVAX

Receive News & Stock Ratings for Dynavax Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corp. and related stocks with our FREE daily email newsletter.